Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir - Wikidata - awgldk - TriplyDB

Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir

Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir

http://www.wikidata.org/entity/Q37247594

about

Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients.Acute Herpetic Keratitis: What is the Role for Ganciclovir Ophthalmic Gel?Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation.Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection.Sex differences in transplantation.Therapeutic drug monitoring of anti-infective agents in critically ill patients.Ganciclovir concentrations in the cerebral extracellular space after valganciclovir treatment; a case study.Antimicrobial Agents

P2860

Q33522300-5A9A4366-0D35-40C1-9E0B-0A3D58AAD5F4 Q34065300-F2438BAB-AC9F-4E46-84B1-4573784F7ACA Q36748051-F2606F40-224C-4AFD-BEB9-5C25DEDE5EA7 Q36969893-6F47D2B1-8172-4F3F-B9C5-B2B0F257EE06 Q37724248-5808C1CF-A563-4324-8C7A-A931D2E580F0 Q37949634-6B3D54DB-86BE-43C6-A19A-13708E696EDA Q38271850-C020DD7A-0240-4388-826B-0D1DCB97A127 Q38750337-2665CD2D-EDB5-4646-B763-914920F806CF Q38790740-D1118FCB-AC90-4426-84CC-799DB7C84CEC Q40869992-7E5C2DCA-3806-4233-9F01-A37743D232FD Q57549163-D6B6F32B-BA24-4542-91CD-D8A4A99708C5

P2860

Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir

http://www.wikidata.org/entity/Q37247594

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Population pharmacokinetics of ...... receiving oral valganciclovir

@en

Population pharmacokinetics of ...... receiving oral valganciclovir.

@nl

type

label

Population pharmacokinetics of ...... receiving oral valganciclovir

@en

Population pharmacokinetics of ...... receiving oral valganciclovir.

@nl

prefLabel

Population pharmacokinetics of ...... receiving oral valganciclovir

@en

Population pharmacokinetics of ...... receiving oral valganciclovir.

@nl

P1433

Q37247594-8BC2FD42-E2FF-4E59-8AEE-7FFBF1E041C7

P1476

Q37247594-D5EE0532-F21F-4D7D-843C-84F56521EBA9

P2093

Q37247594-1596A53C-BBD2-48D6-AC7B-348966A3665F

Q37247594-367E1212-8B08-4B3F-82B4-320EF918C62D

Q37247594-3964E42E-FA50-42A8-AD56-8E998256CA87

Q37247594-A48FD5D7-4F5E-47F2-93EA-89697537B5F8

Q37247594-A77EBA51-C75F-46D4-841B-C313DF46EE02

Q37247594-ADD09E50-22E3-43CF-8B83-6A9974732F81

Q37247594-E05F4697-9122-47F2-AEDC-6F964F84D74C

Q37247594-FA8C8290-846D-4AFB-ABE0-9D87FF51AC73

P2860

Q37247594-037CFA99-4F41-4D10-8727-1AE8EE5E0E38

Q37247594-043F508A-5B5A-496F-BEDB-182ABAD813CE

Q37247594-122192A5-D797-451F-8BE2-8F3EED9522EA

Q37247594-1623EA88-962A-4B87-817A-D79C38AE79A4

Q37247594-2A331A98-B2D5-4715-855D-5591E28551C5

Q37247594-33202299-7821-4A63-B2D4-E3CDC27B4995

Q37247594-50811301-3CC7-4DC4-BD33-B785A8038E0B

Q37247594-5544108B-5A44-44F1-9599-C83216A43F66

Q37247594-66CBE193-565C-4A6D-81F4-733BBC83005B

Q37247594-7360D522-AAB7-4055-90CC-001C39886E22

P304

Q37247594-814D372C-0FBA-47AD-894D-D3A2F972F3D2

P31

Q37247594-BF940347-EF83-40E0-AB50-1F67A41F25E0

P356

Q37247594-BD540F88-2E42-438C-8B1F-962B157E201D

P407

Q37247594-0F1FE68D-6AA4-4919-8DBC-66EB364A4843

P433

Q37247594-552E5638-1C7B-4DEE-BB1A-CF3C97CD007A

P478

Q37247594-1DF639FB-7128-4CCF-A0EE-681D4D063F0D

P50

Q37247594-4BAC56D0-B422-403A-A592-B55A11C4C6BC

Q37247594-69B9FA59-0CC0-4FA3-A13B-96619AC35605

Q37247594-6AE7C27F-8439-43BD-B9B8-DE84A5DD783F

Q37247594-F41B7204-FE87-49D1-8940-5C703FD45162

P577

Q37247594-D238F971-3FBF-4855-8F8B-A3585DBB8256

P698

Q37247594-B4A6B409-9FF9-4E8E-A8DC-D20AB8E799B2

P932

Q37247594-A3A82EC4-E303-48CD-8C02-B0CC1E63E5AD

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Population pharmacokinetics of ...... receiving oral valganciclovir

@en

P2093

J Biollaz

http://www.w3.org/2001/XMLSchema#string

J D Aubert

http://www.w3.org/2001/XMLSchema#string

J P Venetz

http://www.w3.org/2001/XMLSchema#string

L A Decosterd

http://www.w3.org/2001/XMLSchema#string

M Pascual

http://www.w3.org/2001/XMLSchema#string

N Perrottet

http://www.w3.org/2001/XMLSchema#string

P Meylan

http://www.w3.org/2001/XMLSchema#string

P Soccal

http://www.w3.org/2001/XMLSchema#string

P2860

Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients

Prediction of creatinine clearance from serum creatinine

Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects.

Infection in organ-transplant recipients.

Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro.

Transporters and renal drug elimination.

Ganciclovir in solid organ transplant recipients: is there a role for clinical pharmacokinetic monitoring?

Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report.

Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients.

The pharmacokinetics and safety profile of oral ganciclovir in combination with trimethoprim in HIV- and CMV-seropositive patients.

P304

3017-3023

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00836-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

Frédéric Lamoth

P577

2009-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19307355

http://www.w3.org/2001/XMLSchema#string

P932

2704634

http://www.w3.org/2001/XMLSchema#string